TVGNGeneral
▼ -7.6%on this news
Tevogen Announces Formation of a Healthcare Services Initiative
Tevogen Bio Holdings Inc. has announced the establishment of a healthcare services initiative led by interim head William Keane. This initiative aims to support the company's evolution into a revenue-generating healthcare enterprise, with potential acquisitions in Management Services Organizations and Contract Research Organizations. The company estimates that these acquisitions could contribute approximately $100 million to its annual revenue, enhancing its commitment to affordable healthcare. Tevogen emphasizes a disciplined approach in evaluating these opportunities to ensure alignment with long-term strategic goals.
Read more →TVGNGeneral
▲ +11.8%on this news
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
Tevogen Bio Holdings Inc. has announced progress in its strategic acquisition initiatives, potentially leading to approximately $100 million in combined annual revenue. The company aims to evolve into a financially self-sufficient healthcare enterprise by exploring acquisitions that complement its existing biotechnology and technology arms. While the initiatives present significant financial potential, they are dependent on due diligence and approvals, and their success is uncertain.
Read more →TVGNGeneral
▲ +10.4%on this news· ran to -31% by day 3
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
Tevogen Bio Holdings Inc. has signed a Letter of Intent to explore a potential acquisition of a Management Services Organization. This move is aimed at enhancing its healthcare infrastructure and supports the company's evolution into a revenue-generating entity. The CEO expressed that, if successful, the transaction could contribute to an estimated $100 million in annual revenue. However, the completion of the deal is contingent on due diligence, negotiation, and approval processes, which presents inherent uncertainties.
Read more →TVGNGeneral
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
Tevogen Bio Holdings Inc. has announced a $3 million private investment with The Patel Family, LLP, priced at a 14% premium to its latest closing price. This investment aims to enhance Tevogen's operational capabilities, support growth initiatives, and solidify its financial foundation. The financing agreement involves the issuance of 375,000 prefunded warrants, which will close on May 13, 2026. Tevogen's management expressed optimism about the financing's potential benefits in achieving significant revenue milestones.
Read more →TVGNGeneral
▼ -7.3%on this news
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Tevogen Bio Holdings Inc. has announced significant advancements in its AI initiative, Tevogen.AI, with the PredicTcell™ training algorithm nearing completion. The model has shown a 10% improvement in precision and the company is exploring partnerships to enhance its application. Additionally, an internal application portal has been developed to streamline workflows and support future commercial efforts.
Read more →TVGNGeneral
▼ -8.3%on this news
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen Bio Holdings Inc. is evaluating a niche contract research organization (CRO) to enhance its clinical research capabilities and drive revenue growth. This strategic move could contribute over $20 million annually and support the company's goal of achieving closer to $100 million in revenue. The initiative aligns with Tevogen's mission to provide affordable healthcare solutions in oncology and rare diseases.
Read more →TVGNGeneral
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tevogen Bio Holdings Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after facing non-compliance in September 2025. The company aims to transform into a comprehensive healthcare enterprise by combining immunotherapy and artificial intelligence while exploring new strategic initiatives. These initiatives focus on enhancing patient access and affordability while aiming for a cash-flow-positive model. Tevogen's pipeline spans several therapeutic areas, reflecting its commitment to sustainable innovation in healthcare.
Read more →TVGNConferences/Events
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Tevogen Bio Holdings Inc. announced that Mittul Mehta, the Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026) in March 2026. His sessions will focus on the intersection of data engineering and artificial intelligence, addressing modernizing data architecture and building adaptive data pipelines. These themes align with Tevogen.AI's efforts to utilize advanced machine learning to improve biomedical discovery and patient treatment solutions. This participation highlights Tevogen's commitment to integrating cutting-edge technology in healthcare.
Read more →TVGNGeneral
▼ -15.7%on this newsshared move
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
Tevogen Bio Holdings Inc. has reported advancements in its artificial intelligence platform, Tevogen.AI, specifically in the PredicTcell™ model. The company achieved significant improvements in prediction accuracy, with recall increasing to 92% and precision rising to 48%. Additionally, Tevogen.AI has expanded its proprietary database to over 655 million peptide sequences, enabling more robust model training and target identification. The company plans to explore partnerships to advance its peptide candidates as predictive accuracy continues to improve.
Read more →TVGNGeneral
▼ -15.7%on this newsshared move
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Tevogen has provided a strategic update emphasizing its commitment to capital discipline, including the decision to limit share utilization to no more than 1% of its authorized shares in the coming year. The lead investor has expressed strong confidence in Tevogen's growth potential and proprietary technology. Additionally, the company is evaluating acquisitions that could generate over $50 million in annual revenue and is considering a one-time special cash dividend based on future financial milestones. Tevogen's approach reflects a dedication to long-term value creation and operational efficiency.
Read more →TVGNGeneral
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
Tevogen, led by CEO Dr. Ryan Saadi, has reiterated its commitment to clinical development during International Long COVID Awareness Month. The company is advancing its investigational T-cell therapy, TVGN 489, and evaluating the acquisition of the Sciometrix Clinicus platform for real-world monitoring of Long COVID patients. Recent proof-of-concept results show that all treated high-risk patients did not develop Long COVID. With plans to expand its HLA target coverage, Tevogen aims to enhance accessibility for a larger portion of the U.S. population.
Read more →TVGNGeneral
▲ +6%on this newsshared move
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Tevogen Bio Holdings Inc. has appointed interim leaders across its core business sectors to implement a diversified growth strategy. This strategy aims to explore opportunities that could generate over $50 million in annual revenues, with expected closures by Q2 2026. The company is leveraging advanced technologies in healthcare, including AI and precision T cell therapies, to enhance its offerings.
Read more →TVGNGeneral
▼ -16.7%on this newsshared move
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
Tevogen Bio Holdings Inc. has signed a non-binding letter of intent to evaluate the potential acquisition of Apozeal Pharmaceutical, aimed at enhancing Tevogen's generics strategy. This transaction could provide Tevogen with an established platform that includes multiple FDA-approved generic drugs and new products in development, supporting its goal of improving pharmaceutical affordability in the U.S. However, the deal is contingent on due diligence, negotiation, and other conditions, with no assurance it will be finalized. Additionally, Tevogen is considering other life sciences-related transactions, although potential challenges remain.
Read more →TVGNGeneral
▼ -24.8%on this news· ran to -37% by day 3shared move
Tevogen Announces Reverse Stock Split
Tevogen Bio Holdings Inc. has announced a reverse stock split of 50-for-1 to comply with Nasdaq's minimum bid price requirement. The split, approved by stockholders, will take effect on March 6, 2026, and will not affect stockholders' ownership percentages, except for fractional shares. The company continues to focus on its innovative healthcare initiatives.
Read more →TVGNGeneral
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
Tevogen Bio Holdings Inc. has signed a non-binding Letter of Intent to evaluate a potential acquisition of Sciometrix Inc., a healthcare technology provider. This transaction aims to enhance Tevogen's capabilities and establish it as a revenue-generating healthcare enterprise. The deal is subject to due diligence and other customary conditions, with no assurance of completion.
Read more →TVGNGeneral
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
Tevogen Bio Holdings Inc. announced that its Board of Directors will evaluate the possibility of a one-time special cash dividend for shareholders, contingent upon achieving specific financial milestones. The initiative reflects the company's performance and capital requirements, but there is no guarantee regarding the timing or amount of any potential dividend. Tevogen, which operates in the healthcare sector, emphasizes its commitment to advancing therapies while addressing various risks that could affect its operational performance.
Read more →TVGNGeneral
▼ -5.9%on this newsshared move
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
Tevogen Bio Holdings Inc. announced a modification to its long-term stock incentive program, aligning awards with defined company milestones, including revenue. The company aims to launch four blockbuster products by 2030 while leveraging healthcare AI and T cell therapy innovations. This program will affect all eligible employees, signaling Tevogen's commitment to growth and operational efficiency. Despite positive prospects, potential challenges remain regarding competition, regulatory approvals, and capital needs.
Read more →TVGNGeneral
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
Tevogen Bio Holdings Inc. reported significant milestones in 2025, showcasing advancements in its ExacTcell™ platform and expanding its cytotoxic T lymphocyte pipeline. The company is establishing in-house GMP manufacturing capabilities and has identified new targets for its SARS-CoV-2-specific CTL product. CEO Ryan Saadi emphasized the company's commitment to translating scientific advancements into clinical outcomes.
Read more →TVGNGeneral
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
Tevogen Bio Holdings Inc. CEO, Dr. Ryan Saadi, has donated 230,000 shares of the company's common stock to SRLC USA, a nonprofit organization that supports underserved communities. The donation aligns with Tevogen's mission to promote affordable healthcare and reflects a commitment to social responsibility. The company is also known for its advancements in precision T cell therapy and AI tools for drug development. Tevogen aims to broaden patient access through innovative approaches in healthcare.
Read more →TVGNGeneral
Tevogen CEO Donates Personal Shares to Support Local Fire Department
Tevogen's CEO, Dr. Ryan Saadi, has donated 50,000 shares of his personal stock to the Mt. Bethel Fire Company, emphasizing his commitment to local first responders and the community. The donation aims to improve safety and emergency response capabilities. Tevogen is recognized for its innovative healthcare solutions and significant asset valuation.
Read more →TVGNGeneral
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
Tevogen's CEO, Dr. Ryan Saadi, has donated 230,000 shares to the Warren Township Honorary Policemen’s Benevolent Association. This donation aims to support local law enforcement by funding critical safety equipment. The gesture emphasizes the importance of community support for police efforts and reflects Tevogen's commitment to social responsibility.
Read more →TVGNGeneral
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
Tevogen Bio Holdings Inc. celebrates Dr. Curtis Patton, a founding board member, who is honored with a portrait by Yale University for his extensive contributions to medical education and public health. The unveiling of the portrait will take place on December 11, 2025. Dr. Patton's leadership has been pivotal in advancing Tevogen's precision T cell platform and growth strategies aimed at improving patient outcomes.
Read more →TVGNGeneral
▲ +7.2%on this newsshared move
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Tevogen Bio Holdings Inc. has been named to the 2025 NJBIZ Power List, highlighting its influence in New Jersey's economic landscape. The company is recognized for its innovative ExacTcell™ platform and a promising pipeline in various therapeutic areas. Tevogen anticipates significant revenue growth, projecting nearly $1 billion in its first year. The company is also expanding its facilities to enhance R&D and manufacturing capabilities.
Read more →TVGNGeneral
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
Tevogen Bio Holdings Inc. announced its Q3 2025 results, highlighting a significant reduction in operating losses and a commitment to capital efficiency. The company reported a 51% decrease in operating loss for the nine months ended September 30, 2025, while expanding its workforce and infrastructure. Tevogen emphasizes its innovative approach to drug development amid industry challenges.
Read more →TVGNPhases
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
Tevogen Bio Holdings Inc. has achieved a significant clinical milestone by completing T cell target identification for five additional HLA restrictions. This advancement broadens the accessibility of its ExacTcell™ precision T cell therapies, allowing treatment for approximately 65% of the U.S. population, including high-risk patients with acute COVID-19 and Long COVID. The company aims to provide durable immune-based treatments for diverse patient backgrounds.
Read more →TVGNGeneral
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
Tevogen Bio Holdings Inc. has clarified its financial position, addressing the $129 million accumulated deficit reported under GAAP. The company plans to provide non-GAAP metrics to give investors a clearer picture of its financial health. Despite the deficit, Tevogen emphasizes its strong capital efficiency and low cash burn, aiming to enhance investor understanding.
Read more →TVGNGeneral
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
Tevogen Bio Holdings Inc. is actively engaging with community and industry leaders to promote its biopharma model focused on sustainability and affordability. The company highlights its advancements in precision medicine, particularly with its TVGN 489 therapy aimed at treating Long COVID and other diseases. Recent patent filings further demonstrate Tevogen's commitment to innovation in viral infection treatments.
Read more →TVGNPhases
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
Tevogen Bio Holdings Inc. has reported increasing interest in its investigational T cell therapy, TVGN 489, aimed at treating COVID-19 and Long COVID. The company has completed a dose-finding clinical trial with positive safety results and is preparing for the next development phase. Tevogen plans to collaborate with various organizations to enhance patient access once regulatory pathways permit.
Read more →TVGNGeneral
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
Tevogen Bio Holdings Inc. has made significant strides in its PredicTcell platform, enhancing T-cell therapy efficacy through advanced AI. The alpha version demonstrated impressive precision and recall rates, indicating strong potential for immunotherapy. Supported by Microsoft and Databricks, the initiative aims to revolutionize precision medicine, though challenges such as capital needs and regulatory risks remain.
Read more →TVGNPhases
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
Tevogen Bio Holdings Inc. has highlighted the potential of its investigational therapy, TVGN 489, in addressing Long COVID by targeting persistent viral reservoirs. Recent studies suggest that residual SARS-CoV-2 proteins contribute to chronic symptoms. TVGN 489, a precision T cell therapy, demonstrated efficacy in reducing viral load in clinical trials. The company is preparing for clinical manufacturing while acknowledging the need for further research.
Read more →TVGNGeneral
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
Tevogen Bio Holdings Inc. has praised the U.S. Department of Health and Human Services for its efforts in addressing Long COVID through recent roundtables. The company believes its investigational drug, TVGN 489, could significantly impact the lives of the 20 million Americans suffering from this condition. Tevogen emphasizes its commitment to developing innovative therapies to combat Long COVID and improve patient outcomes.
Read more →TVGNConferences/Events
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
Tevogen Bio Holdings Inc. announced that Mittul Mehta, CIO and Head of Tevogen.AI, will be a panelist at the Startup Forum during the Databricks DATA + AI World Tour in Boston on October 8, 2025. The forum will focus on scaling companies with Databricks, featuring discussions on Tevogen.AI's advanced data technologies, including the PredicTcell™ platform. This event underscores Tevogen's commitment to precision immunotherapy development.
Read more →TVGNGeneral
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
Tevogen Bio Holdings Inc. has announced an estimated 5-year top-line revenue of approximately $6.5 billion for its liver cancer prevention product, TVGN 116, aimed at patients with high-risk chronic Hepatitis B infections. The company highlights its innovative drug development model, which contributes to this optimistic forecast. However, there are potential risks related to capital requirements and regulatory hurdles that could impact future performance.
Read more →TVGNPhases
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
Tevogen Bio Holdings Inc. has announced an estimated risk-adjusted net present value (rNPV) of $9 to $11 billion for its first clinical product, TVGN-489, a T cell therapy targeting SARS-CoV-2 and Long-COVID. The therapy has shown promising results in early clinical trials, particularly in patients undergoing stem cell transplants. However, the company faces challenges such as potential capital needs and regulatory hurdles.
Read more →TVGNGeneral
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) recently released an estimation of the valuation and potential forecast for its pipeline product, TVGN 930, aimed at treating hematologic malignancies linked to Epstein-Barr Virus (EBV). The risk-adjusted net present value for TVGN 930 is projected to surpass $250 million, with an anticipated revenue of approximately $3.5 billion over the next five years. The announcement emphasizes the significant therapeutic gap present in treating these malignancies, highlighting the need for effective treatments as no approved vaccines exist for EBV. Moreover, the company's rapid pace in drug development for TVGN 489 illustrates its innovative approach to meet these unmet medical needs.
Read more →TVGNPhases
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
Tevogen Bio Holdings Inc. has emphasized the ongoing need for COVID-19 treatments, especially for individuals with weakened immune systems. Their investigational therapy, TVGN 489, has shown promising results in clinical trials, demonstrating over 99% viral elimination and faster symptom resolution compared to standard care. This therapy is designed to target the entire SARS-CoV-2 genome, making it resilient against viral mutations. The company also highlighted the importance of continuous monitoring and treatment options for high-risk populations as COVID-19 remains a threat year-round.
Read more →TVGNGeneral
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
Tevogen Bio Holdings Inc. has updated its investors on significant proprietary assets that are currently not reflected on its balance sheet but hold substantial long-term value. The company plans to disclose detailed information about these assets soon, highlighting its intellectual property portfolio, drug development platforms, and strategic partnerships. Tevogen is positioned for growth with a well-capitalized structure and ongoing efforts to establish its own manufacturing capabilities. However, the company acknowledges potential risks involving capital needs and competitive market changes.
Read more →TVGNGeneral
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
Tevogen Bio Holdings Inc. expressed gratitude to Yale University for recognizing CEO Dr. Ryan Saadi and the company's mission of health equity. Dr. Saadi was commended for his vision to make healthcare more affordable and accessible. Tevogen's business model is designed to withstand market pressures, focusing on cost-effective, off-the-shelf therapies. However, the company faces potential challenges, including the need for additional capital and uncertainties in growth execution.
Read more →TVGNGeneral
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
Tevogen Bio Holdings Inc. reported a significant increase in institutional ownership, with a 24% rise in Q2 2025, following a notable 60% increase in the previous quarter. Notably, major firms like Morgan Stanley and BlackRock boosted their holdings by 80%. As a result, 72% of the institutional holders either increased or maintained their positions. This growth is interpreted as a potentially positive reflection of Tevogen's operational advancements and clinical data progress.
Read more →TVGNGeneral
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
Tevogen Bio Holdings Inc. has been recognized in BINJE's BEST Health Care 2025 for its advancements in health equity and sustainable biopharma. The accolade acknowledges CEO Ryan Saadi's dedication to ensuring access to life-saving medications through an innovative approach. Tevogen is focused on affordable T cell therapies and operates with a lean, capital-efficient model. Its proprietary ExacTcell™ platform has shown promising results in early clinical trials, emphasizing the company's commitment to addressing healthcare priorities in the U.S.
Read more →TVGNGeneral
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
Tevogen Bio Holdings Inc. reported its financial results for the second quarter of 2025, showcasing reduced operational losses of $5.4 million compared to $8.6 million in Q2 2024. The company highlighted improved capital efficiency and access to financing that supports its growth strategies. Additionally, Tevogen is focused on building its infrastructure and advancing artificial intelligence to enhance its internal capabilities. The firm is also in the process of establishing its own GMP manufacturing facility to control production better and speed up product development timelines.
Read more →TVGNGeneral
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
Tevogen CEO Dr. Ryan Saadi has donated 10,000 shares of his personal stock to the Opportunity Project, a nonprofit organization focused on aiding individuals with brain injuries. This contribution aims to support the nonprofit's innovative programs that foster independence and community reintegration. Dr. Saadi expressed his admiration for the Opportunity Project's impactful work, reaffirming his commitment to community support. The donation occurred under SEC Rule 144, ensuring no proceeds were received by Dr. Saadi from the transaction.
Read more →TVGNGeneral
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
Tevogen CEO Dr. Ryan Saadi has donated 10,000 of his personal shares to the Warren Township Honorary Policemen's Benevolent Association. The P.B.A. is a non-profit organization that supports local schools and charitable causes. Saadi expressed his honor in contributing to the organization's mission, which fosters relationships between law enforcement and the community. This generous act highlights Tevogen's commitment to local initiatives.
Read more →TVGNGeneral
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
Tevogen Bio Holdings Inc. announced the upcoming release of a comprehensive inventory detailing its internally developed assets along with their valuation methodology. The company's CEO, Dr. Ryan Saadi, highlighted the significant value of these assets, which are not reflected in financial reports due to accounting rules. He reassured shareholders of the complete protection of the company's intellectual property and proprietary technologies. However, the company faces challenges, including potential capital needs and market competition, which could impact its growth strategies.
Read more →TVGNGeneral
▲ +8.8%on this newsshared move
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
Tevogen Bio Holdings Inc. has reaffirmed investor confidence with its estimated asset value exceeding $10 billion. This valuation reflects the company's robust intellectual property and product portfolio, which is anticipated to generate significant revenue. Notable investors, including HMP Partners, praised Tevogen's leadership and successful milestones, including patents and a promising product pipeline. The company's founder, Dr. Ryan Saadi, emphasized the potential of their platform technologies and plans to share further details with the investment community.
Read more →TVGNGeneral
▲ +8.8%on this newsshared move
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
Tevogen Bio has announced an optimistic revenue forecast for its oncology pipeline, expecting to generate $1 billion in its first year and between $10 billion and $14 billion cumulatively over five years. This forecast is bolstered by the company's commitment to patient accessibility and innovative treatment methods, especially for cancer patients at risk from SARS-CoV-2. The company emphasizes a unique drug development approach which could redefine sustainability in medical innovation. However, there are concerns regarding the need for additional capital, operational challenges, and potential legal risks that could affect future performance.
Read more →TVGNGeneral
▼ -8.7%on this newsshared move
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
Tevogen Bio Holdings Inc. has announced the receipt of $1 million in funding to advance its Tevogen.AI initiative, an artificial intelligence-driven drug discovery program. This funding is part of a previously disclosed agreement with KRHP LLC, which could total up to $10 million. The financial support will enable better target discovery and shorter development timelines for treatments in oncology and infectious diseases. Tevogen remains well-capitalized with additional resources, further strengthening its operational efficiency and growth potential.
Read more →TVGNGeneral
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
Tevogen Bio Holdings Inc. has reported a significant 60% increase in institutional ownership of its common stock as of March 31, 2025. Major contributors to this growth include Vanguard and BlackRock, which raised their holdings by 151%. The company noted that 73% of institutional investors either increased their positions or maintained them. Tevogen is also advancing its potential in targeted therapies for cancers and infectious diseases, alongside establishing its own GMP cell manufacturing facility.
Read more →TVGNGeneral
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Tevogen Bio Holdings Inc. (TVGN) announced an expansion of its collaboration with Microsoft and Databricks to develop a beta version of its PredicTcell model, focusing on oncology targets. This advancement aims to improve the model's accuracy and diversity, which may accelerate the development of cancer immunotherapy. The project is supported by Tevogen.AI's recently published international patent application for machine learning systems to predict immunologically active peptides. As part of this initiative, Tevogen.AI will also enhance analytics and visualization tools for better internal R&D support.
Read more →TVGNGeneral
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Tevogen Bio Holdings Inc. has reported strong growth and a robust capital position in a recent letter to stockholders. The company is expanding its operations into artificial intelligence with the launch of its PredicTcell platform and has established strategic partnerships with technology giants. They have made significant advancements in drug development and infrastructure, bolstered by a solid insider ownership percentage. Tevogen emphasizes its commitment to delivering affordable and impactful healthcare solutions.
Read more →TVGNGeneral
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
Tevogen Bio Holdings Inc. has announced an additional $1 million grant funding to advance its AI-driven drug discovery initiative, Tevogen.AI. This funding is part of a larger $10 million grant agreement with KRHP LLC, which aims to enhance the company’s capabilities in target discovery and treatment accessibility. The CEO emphasized the potential of Tevogen.AI in accelerating drug development and expanding access to therapies for patients. The company continues to focus on operational efficiency to maximize shareholder value.
Read more →TVGNGeneral
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
Tevogen Bio Holdings Inc. announced that its executive officers and board members hold over 74% of the company's outstanding shares, signaling a strong commitment to the company's vision and strategy. CEO Dr. Ryan Saadi stated that this majority control is essential for sustaining decision-making and growth. The company is also well-funded for the development of its genetically unmodified T cell therapeutics and artificial intelligence projects. Despite these strengths, the company faces challenges such as the potential need for additional capital and risks related to competition and growth management.
Read more →TVGNGeneral
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
Tevogen.AI has expressed strong support for the U.S. government's AI Action Plan aimed at enhancing healthcare innovation. The company has developed PredicTcell™, a new machine learning model that potentially streamlines immunotherapy research, saving time and costs. Tevogen's CEO emphasized the importance of AI in making advanced therapeutics more accessible to patients, aligning with the government’s strategic focus on equitable healthcare solutions. This initiative marks a significant step in advancing AI technology within the biopharmaceutical sector.
Read more →TVGNGeneral
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
Tevogen Bio Holdings Inc. announced the publication of its international patent covering AI technology for predicting immunologically active peptides. This technology aims to improve the identification of peptides that can target diseases effectively, including cancers and infectious diseases. The patented methods leverage machine learning and are supported by industry partnerships with Microsoft and Databricks. The company envisions accelerated discovery and cost-effective development of personalized therapies through this innovative approach.
Read more →TVGNGeneral
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
Tevogen Bio Holdings Inc. has signed a letter of intent to lease a 17,428-square-foot manufacturing facility in New Jersey, focusing on GMP cell therapy production. This facility aims to improve the company's clinical development processes while ensuring scalability and cost efficiency. Dr. Ryan Saadi, CEO, emphasized the potential of this facility to aid in bridging phases of manufacturing and advancing Tevogen's product pipeline. However, the company faces challenges, including potential funding needs and various operational risks.
Read more →TVGNGeneral
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
Tevogen Bio Holdings Inc. has announced an expansion of its AI platform, Tevogen.AI, following the completion of the alpha version of its PredicTcell™ model. This initiative aims to improve patient identification for clinical trials by rapidly analyzing electronic health records. Supported by partnerships with major tech companies, the new system is designed to expedite the time-to-market for therapies in the ExacTcell™ pipeline. However, the company faces several risks, including potential capital shortages and regulatory challenges in clinical trial execution.
Read more →TVGNGeneral
▲ +5.9%on this newsshared move
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
Tevogen.AI has announced the successful development of the alpha version of its PredicTcell™ model in collaboration with Microsoft and Databricks. This AI-driven model drastically reduces the time required for target analysis and is expected to create significant cost savings in drug development. The initiative also aims to expand its application to oncology, enhancing cancer immunotherapy development. Tevogen.AI plans to further innovate in clinical trials and patient analysis through additional models in the future.
Read more →TVGNGeneral
Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
Tevogen Bio Holdings Inc. has officially opened its expanded corporate headquarters in Warren, New Jersey, fully funded by CEO Ryan Saadi. The new facility doubles the company's previous space and consolidates cross-functional teams, enhancing capacity for research and the Tevogen.AI initiative. A ribbon-cutting ceremony is planned to celebrate the opening. Tevogen's expansion aims to enable significant growth and innovation in the therapeutic landscape.
Read more →TVGNGeneral
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
Tevogen Bio Holdings Inc. announces a significant investment from CEO Ryan Saadi, who contributed $500,000 to support the build-out and operational costs of the company’s new corporate headquarters in Warren, New Jersey. The new facility will enable Tevogen to centralize its teams and enhance collaboration, particularly in relation to its AI-driven platforms for cell therapies. This decision underscores the leadership's commitment to the company's mission and long-term vision in the biopharmaceutical sector. The investment aims to facilitate efficient scaling while maintaining capital discipline.
Read more →TVGNPhases
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
Tevogen Bio Holdings Inc. has provided an update on the development of its EBV-specific T cell therapy aimed at treating EBV-associated lymphomas. The company is utilizing its proprietary ExacTcell™ technology and incorporating AI to enhance peptide selection for the therapy. As part of this initiative, Tevogen is conducting studies to validate CTL responses to selected viral peptides, aiming for improved precision in treatment. The collaboration with Tevogen.AI signifies a strategic approach to accelerate the identification of immunologically active targets. The company intends to share further updates as research progresses.
Read more →TVGNGeneral
▼ -23.1%on this news
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
Tevogen has announced the expansion of its corporate headquarters in Warren, New Jersey, aiming to centralize operations to improve efficiency and collaboration across teams. This move is expected to support the company's diversifying initiatives including Tevogen.AI and its Generics & Biosimilars effort. The firm anticipates substantial revenues from its oncology and specialty care sectors, with a market valuation update on its AI assets expected soon. The expansion is seen as a critical step in advancing healthcare innovation and accessibility through in-house manufacturing and AI-powered drug development.
Read more →TVGNGeneral
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
Tevogen Bio Holdings Inc. (TVGN) has introduced its artificial intelligence initiative, Tevogen.AI, which integrates machine learning with its ExacTcell technology to improve immunotherapy development. The initiative is backed by strategic partnerships with Microsoft and Databricks, aimed at accelerating drug discovery and enhancing predictive modeling. Tevogen plans to expand its headquarters to support the initiative, which includes innovative proprietary technologies that could significantly impact healthcare and therapeutic strategies. The company is committed to transparently updating stakeholders on its progress.
Read more →TVGNGeneral
▲ +6.5%on this news
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
Tevogen Bio has announced plans to widen the target population for its TVGN 489 treatment to include patients aged 65 and older, building upon a previously projected revenue forecast of nearly $1 billion in its launch year. The updated estimate for the specialty care pipeline foresees substantial cumulative revenues over five years. The Chief Commercial Officer highlighted the company's focus on addressing significant unmet medical needs with the expansion. New risks include potential challenges in raising capital and managing operational growth.
Read more →TVGNGeneral
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
Tevogen Bio Holdings Inc. plans to update stockholders on its robust portfolio and strategic growth initiatives before the June 23, 2025 Annual Meeting. With assets valued over $10 billion, the company emphasizes its innovative business model, highlighting expansions like Tevogen.AI and Tevogen Generics & Biosimilars. It also notes the impact of its limited tradable float and the increasing institutional ownership evidencing strong investor confidence. However, the company faces risks related to capital requirements and changing market dynamics.
Read more →TVGNGeneral
▲ +9.2%on this news
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
Tevogen Bio is addressing critical challenges in the biopharma industry through its innovative, cost-efficient business model. Amid increasing global competition and calls for affordable healthcare, Tevogen aims to lead in redefining healthcare economics. Their strategic focus includes ensuring sustainability while delivering groundbreaking medical innovations. However, the company faces risks related to the need for additional capital, competitive dynamics, and its limited operating history.
Read more →TVGNGeneral
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
Tevogen Bio Holdings Inc. announced an increase in shareholder inquiries regarding the Direct Registration System (DRS) following a recent press release. The company plans to provide detailed guidance to help shareholders transfer their shares into DRS accounts. The interest from both internal and external significant shareholders reflects a strong confidence in the DRS as a secure method of ownership.
Read more →TVGNConferences/Events
▲ +7.7%on this newsshared move
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
Tevogen Bio Holdings Inc. CEO Dr. Ryan Saadi is set to participate in the panel discussion 'Paths to Liquidity: Strategies for Adapting to a Volatile Market' at BioNJ's Fifteenth Annual Bio Partnering Conference. The event, scheduled for May 13, 2025, will gather industry leaders and investors to discuss strategies for navigating market challenges. Dr. Saadi emphasized the importance of addressing market volatility for improving patient outcomes, aligning with Tevogen's mission. The conference will feature various opportunities for collaboration and networking among professionals in the biotechnology sector.
Read more →TVGNGeneral
▲ +7.7%on this newsshared move
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
Tevogen Bio Holdings Inc. has informed shareholders about the differences between Direct Registration System (DRS) accounts and brokerage accounts. DRS accounts allow shares to be registered directly in the shareholder's name, potentially reducing transaction and maintenance costs. While brokerage accounts may offer quicker selling options and access to various tools, shareholders are encouraged to consider the benefits of DRS accounts.
Read more →TVGNGeneral
▼ -5.5%on this newsshared move
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
Tevogen Bio Holdings Inc. has reaffirmed a top-line revenue forecast of $1 billion for its oncology pipeline in its launch year, with a five-year cumulative estimate ranging from $10 billion to $14 billion. The forecast is based on the company's efficient drug development model. Additionally, Tevogen has entered into an agreement with CD8 Technology Services LLC to secure up to $50 million for its R&D and manufacturing facility. However, the company faces challenges such as potential capital raising needs and regulatory hurdles that may affect its growth prospects.
Read more →TVGNConferences/Events
Tevogen Bio Announces 2025 Annual Meeting
Tevogen Bio Holdings Inc. announced its 2025 annual meeting of stockholders to be held via live webcast on June 23, 2025. Stockholders of record as of April 30, 2025, will have the opportunity to vote on the re-election of two directors and the ratification of the independent auditor. Proxy materials will be distributed in compliance with SEC regulations, and the results of the meeting will be disclosed in a Form 8-K afterward. The company has made provisions for stockholders to obtain necessary voting information and participate in the meeting.
Read more →TVGNGeneral
Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilities Formalized agreement aligns with
Tevogen Bio has finalized an agreement with CD8 Technology Services for the development and acquisition of a turn-key facility aimed at enhancing its cell therapy production capabilities. This facility will support both pre-clinical research and GMP production, aligning with the company's strategic goals to accelerate development timelines and control costs. The collaboration is expected to assist Tevogen in overcoming capital barriers typically faced in building GMP capabilities at scale. Specific operational details will be established in forthcoming work orders.
Read more →TVGNGeneral
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
Tevogen Bio Holdings Inc. has commissioned Databricks, Inc. to accelerate the development of PredicTcell, an AI-driven model for precision immunotherapy. This partnership aims to enhance the capabilities of the predictive model focused on immunologically active peptides and T cell receptor engagement. The collaboration is part of Tevogen's broader initiative, Tevogen.AI, designed to revolutionize precision medicine through AI technology. The company operates with a commitment to providing affordable healthcare solutions, but faces potential challenges in capital acquisition and regulatory hurdles.
Read more →TVGNGeneral
▲ +16.7%on this newsshared move
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
Tevogen Bio Holdings Inc. has launched Tevogen Generics, a new initiative aimed at enhancing the affordability of pharmaceuticals in the United States. This initiative aligns with President Trump's efforts to encourage domestic manufacturing of crucial medicines. Sadiq Khan, the company's Chief Commercial Officer, will lead this effort to expedite the production of unbranded pharmaceuticals. Tevogen Generics represents a new strategic direction for the company amidst other initiatives focused on immunotherapy and AI-driven drug discovery.
Read more →TVGNConferences/Events
▼ -6.8%on this newsshared move
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
Tevogen Bio announced that Mittul Mehta, CIO and Head of Tevogen.AI, presented at the AI x Bio Philly event, showcasing AI's impact on biotechnology. The event highlighted Tevogen.AI's technology aimed at developing precision T cell therapies through computational modeling. Tevogen Bio has reported positive data from its clinical trials and has a robust portfolio of patents. The company's leadership emphasizes the importance of accessible therapeutics in the evolving healthcare landscape.
Read more →TVGNGeneral
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
Tevogen Bio Holdings Inc. announced that its executive officers and board members own 74% of the company's shares, reflecting their commitment to its mission in immunotherapy and AI. The company highlighted its unique position compared to peers and pointed out its operations solely within the U.S., which may offer some stability amidst market fluctuations. However, Tevogen has acknowledged potential challenges, including the need for additional capital and the uncertainties associated with clinical trial outcomes and regulatory processes.
Read more →TVGNGeneral
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
Tevogen Bio's CEO, Ryan Saadi, has been named to NJBIZ's 2025 Health Care Power List, recognizing his leadership and innovations in healthcare. The company also appointed David E. Banko as Global Head of Government Affairs to enhance patient access and support commercialization efforts. Tevogen Bio is banking on a projected $1 billion revenue in its launch year, fueled by its promising CD8+ T cell therapy. However, the company faces challenges, including potential capital needs and regulatory hurdles as it pursues its ambitious goals.
Read more →TVGNGeneral
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
Tevogen Bio has announced the appointment of David E. Banko as Global Head of Government Affairs and Patient Access, which is seen as a significant step towards advancing its commercialization strategy. Mr. Banko will drive market access initiatives and collaborate with R&D to support patient accessibility to Tevogen's therapies. His extensive experience in market access and health policy is expected to enhance Tevogen's efforts in improving healthcare outcomes and ensuring timely access to innovative treatments for patients. The company is focused on leveraging its proprietary immunotherapy technologies to meet the needs of large patient populations across various therapeutic areas.
Read more →TVGNGeneral
▼ -7%on this news
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
Tevogen Bio has announced the development of a unique T cell vaccine aimed at stimulating immune responses against viral infections. This vaccine utilizes the company's proprietary AI technology to identify effective peptides, targeting the entire viral genome to mitigate mutation risks. Alongside this, Tevogen filed a patent for the vaccine with the USPTO, hoping to address public inoculation concerns. The company remains committed to transparency and public dialogue during the vaccine's development process, while maintaining its financial forecasts for its other ongoing projects.
Read more →TVGNConferences/Events
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
Mittul Mehta, Chief Information Officer of Tevogen.AI, participated in Proskauer's AI discussion panel in New York City, sharing insights into AI's role in biotech. The panel also featured leaders from other industries, focusing on how AI can enhance operations and precision medicine. Mehta emphasized Tevogen.AI's innovative use of AI to accelerate healthcare solutions. The event facilitated networking among industry professionals, further illustrating the importance of AI in transforming sector practices.
Read more →TVGNGeneral
▼ -7.8%on this news
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
Tevogen Bio is set to receive an additional $8 million grant from KRHP LLC, totaling $10 million, based on a favorable review of its progress, particularly regarding its Tevogen.AI initiative. The company continues to maintain efficient operations with operating expenses recorded at $9.7 million for the first three quarters of 2024, underlining sustainability in its mission to develop innovative therapies targeting cancers and viral infections. This grant supports the advancement of Tevogen's AI-driven PredicTcell platform, enhancing its capabilities in predictive modeling.
Read more →TVGNGeneral
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
Tevogen Bio, led by CEO Dr. Ryan Saadi, has been recognized in the 2025 NJBIZ Power 100 for its contributions toward accessible T cell therapies. The company focuses on developing affordable immunotherapies for viral infections and cancers using its ExacTcell technology, which has shown promising results in clinical trials. The launch of Tevogen.AI and a collaboration with Microsoft represent key steps toward making these therapies more accessible. Dr. Saadi emphasizes this recognition reflects Tevogen's mission to improve healthcare affordability and sustainability.
Read more →TVGNGeneral
▼ -8.7%on this news· ran to -20% by day 3
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
Tevogen Bio has reported a 600% higher market cap per team member compared to the industry average, alongside a 79% insider ownership rate, indicating strong internal confidence. The company, focused on developing precision T cell therapies, aims to challenge traditional biotech norms and promote efficiency alongside drug pricing reforms. Tevogen's leadership emphasizes the importance of sustainability and patient accessibility while facing potential challenges, including the need for additional capital and regulatory uncertainties. Positive safety data from clinical trials further support their optimistic outlook.
Read more →TVGNGeneral
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
Tevogen Bio's CEO, Ryan Saadi, reaffirms the company's commitment to retaining equity capital and enhancing shareholder value amid discussions on biotech financing strategies. Emphasizing operational efficiency and a strong asset base, Tevogen Bio aims to pursue a self-sustaining model that minimizes equity dilution. The company is focused on advancing its immunotherapy product candidates while addressing unmet medical needs in cancer and infectious diseases. Tevogen's strategy involves distinct pathways to funding that do not rely heavily on external equity sales, aiming for long-term sustainability.
Read more →TVGNGeneral
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
Tevogen Bio recently celebrated its first anniversary as a publicly listed company by outlining its financing activities in 2024. Among these, the company secured an $8 million Series A investment and signed a letter of intent for a $50 million R&D facility, both designed to avoid shareholder dilution. The leadership highlighted their commitment to developing personalized T cell therapies, supported by positive safety data from clinical trials, and a strategic operational model aimed at sustaining medical innovation. However, challenges remain, including potential capital-raising needs and competitive market dynamics.
Read more →TVGNGeneral
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
Tevogen Bio's CEO, Dr. Ryan Saadi, highlighted the adverse effects of short-selling on the healthcare sector in a recent statement. He emphasized the company's dedication to develop accessible medical innovations, notably through collaboration with Microsoft for AI advancements. Despite significant progress, the company's share price has been pressured, prompting concerns about the impact of market dynamics on healthcare priorities. Tevogen Bio remains committed to addressing critical patient needs through advanced immunotherapy solutions.
Read more →TVGNGeneral
▼ -6%on this newsshared move
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
Tevogen Bio's CEO, Dr. Ryan Saadi, congratulated Robert F. Kennedy Jr. on his new role as Secretary of Health and Human Services, emphasizing shared goals of affordable healthcare. Tevogen Bio is committed to delivering specialized immunotherapies while ensuring patient accessibility. The company reported positive safety data from its clinical trials and is focused on innovative approaches to meet significant medical needs. However, challenges such as the need for additional capital and regulatory uncertainties remain.
Read more →TVGNGeneral
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
Tevogen Bio recently met with BARDA's TechWatch team to discuss ExacTcell technology, emphasizing its potential as a scalable medical countermeasure. The meeting highlighted positive results from their proof-of-concept trial for TVGN 489 and the integration of artificial intelligence in their processes. Tevogen Bio aims to position ExacTcell to rapidly adapt to new viral threats, contributing to public health initiatives. The company is set to follow up with federal entities to further their advancements.
Read more →TVGNGeneral
▼ -8.9%on this news
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding The grant funding will further Tevogen Bio's mission to develop therapies for treatment of cancers and viral infections. Tevogen Bio
Tevogen Bio, a clinical-stage immunotherapy biotechnology company, announced an agreement to receive up to $10 million of non-dilutive grant funding from KRHP LLC. The initial contribution of $2 million is aimed at supporting the development of T cell therapeutics for cancers and viral infections, with up to an additional $8 million contingent on future evaluations. This grant complements a previously disclosed $36 million loan agreement and aligns with Tevogen's focus on expanding its artificial intelligence initiatives in drug development. The company emphasizes its commitment to operational efficiency and accessibility in therapeutic offerings.
Read more →TVGNGeneral
▲ +24.4%on this newsshared move
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
Tevogen Bio's CEO, Dr. Ryan Saadi, congratulated Lynne Patton on her appointment as Deputy Assistant to the President and Director of Minority Outreach. Patton, who has significant experience in public service and previously worked at HUD, will focus on outreach to underserved communities. The company expresses its commitment to advancing affordable medical innovation and has reported positive data from its clinical trials. However, there are concerns regarding potential capital needs and the impact of recent business combinations on operations.
Read more →TVGNGeneral
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
Tevogen Bio is enhancing its partnership with Microsoft to expand its artificial intelligence efforts and develop its proprietary PredicTcell technology on the Azure platform. This collaboration aims to accelerate the identification of new T cell targets and improve understanding of immune responses. Additionally, Tevogen Bio is exploring potential treatments for HPV, leveraging AI for the analysis of large genomic datasets. The company expects these advancements will enhance its pipeline and could lead to more effective immunotherapies.
Read more →TVGNConferences/Events
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
Tevogen Bio Holdings Inc. showcased its advancements in AI-driven drug development during a fireside chat at the J.P. Morgan Healthcare Conference, emphasizing its commitment to patient equity. The discussion highlighted how AI and machine learning have notably reduced the time and costs associated with drug discovery. Key leaders from both Tevogen and Microsoft stressed the importance of data quality and governance in the responsible deployment of AI technologies in healthcare. Tevogen Bio remains focused on advancing affordable therapeutics and reported positive safety data from its clinical trials, bolstering its innovative approach.
Read more →TVGNConferences/Events
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
Tevogen Bio will host two panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The discussions will focus on 'AI In Biopharma' and 'Pioneering the Economics of Health,' featuring prominent industry leaders as panelists. This event aims to highlight advancements in drug discovery through AI and the importance of addressing healthcare system interdependencies. Tevogen, a clinical-stage immunotherapy company, aims to improve patient access through innovative therapies and business models.
Read more →TVGNConferences/Events
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
Tevogen Bio will host a panel titled "AI in Biopharma: Next Frontier of Medical Innovation" at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The discussion will focus on the potential of artificial intelligence to enhance drug discovery and patient access. Notable panelists include experts from Microsoft and Tevogen.AI. Tevogen Bio aims to develop unmodified T cell therapies for various diseases, with positive safety data reported from its clinical studies.
Read more →TVGNGeneral
▲ +12.1%on this news· ran to +24% by day 3shared move
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
Tevogen Bio has filed for a new patent focused on predictive AI to improve T cell therapies and enhance its intellectual property portfolio. The company is actively integrating artificial intelligence in drug discovery and development, led by newly appointed head Mittul Mehta. Tevogen's AI efforts aim to increase patient access and reduce operational costs, supported by a partnership with Microsoft. The filing reinforces Tevogen's commitment to innovation and positions it for future advancements in immunotherapy.
Read more →TVGNConferences/Events
▼ -5.9%on this newsshared move
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
Tevogen Bio, a clinical-stage immunotherapy company, will host a panel discussion titled 'Pioneering the Economics of Health: Balancing Access and Outcomes' at the 43rd Annual J.P. Morgan Healthcare Conference. The panel aims to address the complexities of healthcare innovation, focusing on patient access, reimbursement mechanisms, and health policy. It will feature distinguished experts discussing the implications of U.S. leadership in healthcare and the effects of cost-containment measures on drug development. Tevogen has noted positive safety data from its clinical trials and highlights the importance of accessibility in personalized therapeutics.
Read more →TVGNConferences/Events
▼ -6.8%on this news
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Tevogen Bio announced its participation in the upcoming J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco, CA. The company, which specializes in developing off-the-shelf, genetically unmodified T cell therapeutics, is led by Founder and CEO Ryan Saadi. Tevogen aims to address significant unmet needs in infectious diseases and cancers and has reported positive safety data from its clinical trials. Its strong patent portfolio positions the company favorably within the industry.
Read more →TVGNGeneral
▼ -5.6%on this news· ran to -17% by day 3
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy
Tevogen Bio has announced an organizational readiness initiative to support its growth strategy, involving additional responsibilities for key leaders. The company has reported a significant reduction in net loss and projects substantial revenue from its oncology and specialty care products. Additionally, Tevogen is establishing a partnership to develop a new R&D and manufacturing facility, strengthening its operational capabilities. Despite these positive developments, potential challenges related to capital needs and market competition could impact future growth.
Read more →TVGNGeneral
▲ +15.5%on this newsshared move
Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value
Tevogen Bio, a biotech developing immunotherapy treatments, has expressed gratitude to its shareholders for their ongoing support. The company reported a notable decrease in net loss and the elimination of almost all liabilities, ensuring sufficient capital for operations for the next 33 months. CEO Ryan Saadi emphasized the significance of preserving shareholder value and indicated potential actions against short selling targeting the company. Tevogen's leadership remains focused on delivering accessible therapies and plans to update stakeholders on progress in the near future.
Read more →TVGNGeneral
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
Tevogen Bio reported its financial results for Q3 2024, noting a significant reduction in net loss from $56.8 million in 2023 to $4.3 million this year. The company has improved its financial stability by eliminating nearly all liabilities, dropping from $99.9 million to $10.5 million. However, the valuation of over $10 billion for its intellectual property and AI assets remains unreported on the balance sheet due to US GAAP standards. Tevogen expressed confidence in its operations, backed by sufficient capital for at least the next 33 months.
Read more →TVGNGeneral
▼ -17.8%on this newsshared move
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
Tevogen Bio, a clinical-stage biotech company, is preparing to file its quarterly financials and reflects on its growth since its founding in 2020. Founder and CEO Ryan Saadi emphasizes the importance of preserving shareholder value while navigating financing options to avoid equity dilution. The company has achieved significant progress with a disciplined approach, staying under $40 million in expenditures and reporting positive clinical trial data. Tevogen aims to leverage its unique asset portfolio while addressing challenges inherent in the biotech industry.
Read more →TVGNGeneral
▲ +7%on this news· ran to +58% by day 3
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
Tevogen Bio is nearing the finalization of an agreement with CD8 Technology for a facility to bolster its R&D and GMP manufacturing. In conjunction with this, the company reaffirms its access to a $36 million line of credit to support ongoing operations and growth. Despite maintaining a solid financial position with no substantial debt, the leadership acknowledges pressures on the stock price and the need for potential additional capital. Tevogen aims to deliver transformative therapies while focusing on shareholder value and sustainable growth.
Read more →TVGNGeneral
▼ -12.2%on this news· ran to -38% by day 3shared move
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
Tevogen Bio, a clinical-stage biotech company, has been recognized by ROI-NJ for the innovative leadership of its CEO, Dr. Ryan Saadi. The company is noted for its effective cost management, boasting over $10 billion in valued assets achieved through under $40 million in spending. Tevogen focuses on developing T cell therapeutics for infectious diseases and cancers, highlighting its commitment to patient accessibility and sustainability in healthcare through advanced scientific approaches. Additionally, the company owns key intellectual property, including patents related to artificial intelligence.
Read more →TVGNPhases
▼ -12.2%on this news· ran to -38% by day 3shared move
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920
Tevogen Bio has initiated a pre-clinical effort for its oncology treatment TVGN 920 in partnership with Microsoft. This collaboration will utilize advanced AI technologies to accelerate target identification for HPV-related therapies. The company has developed a dataset from the HPV genome to identify potential treatment targets, and aims to create a portfolio of oncology products. Additionally, Tevogen has reported positive safety data in its clinical trials, emphasizing its commitment to innovative and accessible therapies.
Read more →TVGNGeneral
▼ -17.3%on this news· ran to -52% by day 3shared move
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support
Tevogen Bio has appointed Anthony Tarantino as its new Patient Advocate, focusing on community engagement and patient support, particularly for at-risk populations such as cancer patients and those suffering from Long COVID. Tarantino, known for his advocacy in firefighter safety and health, brings considerable experience to the role, including previous successes in legislative initiatives. His appointment coincides with Tevogen's advancement of its investigational therapy, TVGN 489, which targets SARS-CoV-2 in vulnerable patient groups. The company aims to leverage Tarantino's expertise to amplify patient voices and strengthen outreach programs.
Read more →TVGNGeneral
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
Tevogen Bio has expanded its partnership with Microsoft to enhance its drug development process by integrating machine learning and AI. The initiative aims to utilize Microsoft's AI tools to accelerate preclinical activities, including rapid target identification and improved understanding of immune responses. Initial projections suggest that drug development timelines could be reduced by approximately 10%, with further advancements potentially leading to a 30% reduction. This partnership supports Tevogen's commitment to developing innovative T cell therapeutics while addressing significant market needs.
Read more →TVGNGeneral
▼ -6.9%on this newsshared move
Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company
Tevogen Bio announced it has regained compliance with Nasdaq listing requirements after successfully maintaining the minimum bid price of $1.00 for over 10 consecutive trading days. The company's CEO emphasized a commitment to preserving shareholder value and highlighted significant revenue forecasts for both Tevogen Oncology and Specialty Care in the upcoming years. The firm continues to advance its pipeline, focusing on innovative cell therapies, while its AI initiative has partnered with Microsoft for growth support. Tevogen has demonstrated promising clinical trial results for its T cell therapies, reflecting its potential in the biotech space.
Read more →TVGNGeneral
▼ -6.9%on this newsshared move
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity
Tevogen Bio has signed a letter of intent with CD8 Technology Services to develop a new R&D and manufacturing facility expected to be worth up to $50 million. This facility aims to support pre-clinical research and good manufacturing practice (GMP) capabilities, thereby expediting the research and manufacturing processes. Tevogen emphasizes its commitment to shareholder value while overcoming capital and time barriers. The company also highlights its unique position with wholly owned patents and a strong leadership team to drive its innovative therapies forward.
Read more →TVGNPhases
▲ +19.1%on this newsshared move
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas
Tevogen Bio has announced updates on its T cell therapy, TVGN 489, aimed at treating SARS-CoV-2 infections in immunocompromised oncology patients and those with post-acute sequelae of SARS-CoV-2. The company aims for market entry by 2026 and reports positive outcomes from early clinical trials. Tevogen's strategy focuses on utilizing advanced science for patient accessibility while maintaining all key intellectual property rights. The firm also highlights its commitment to accelerating development through innovative business practices.
Read more →TVGNGeneral
▲ +54%on this news· ran to +70% by day 3shared move
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development
Tevogen Bio has announced a partnership with Microsoft for Startups to accelerate its artificial intelligence initiative, Tevogen AI. This collaboration aims to leverage Microsoft's technology to enhance drug development efficiency and reduce costs, facilitating the delivery of innovative therapies. Tevogen, a clinical-stage biotech company, is focused on developing off-the-shelf T cell therapies for infectious diseases and cancers. The partnership is viewed as a significant step towards achieving their goals of making personalized therapeutics more accessible to larger patient populations.
Read more →TVGNGeneral
▼ -10.6%on this news· ran to +69% by day 3shared move
Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week
Tevogen Bio, a clinical-stage immunotherapy company, plans to provide updates on its revenue forecasts for oncology and specialty care areas by the week's end, with an estimated $1 billion revenue projected per area upon launch. The company also intends to share developments regarding its artificial intelligence initiative aimed at enhancing drug discovery and reducing development costs. Positive safety results from clinical trials support their therapeutic potential, while ownership of intellectual property may facilitate strategic advantages. However, Tevogen faces potential challenges in capital acquisition and the effects of a recent business combination.
Read more →TVGNGeneral
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
Tevogen Bio has announced a promising revenue forecast for its specialty care pipeline, estimating nearly $1 billion in its launch year and between $18 billion and $22 billion over five years. This projection reflects the company's innovative approach in developing genetically unmodified T cell therapeutics for treating infectious diseases and cancers. The company has also reported positive safety data from its clinical trials. However, there are potential risks related to capital requirements, competition, and regulatory challenges that could impact its financial outlook.
Read more →TVGNGeneral
Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days
Tevogen Bio (Nasdaq: TVGN) clarified that the recent share sales by Chief Scientific Officer Dr. Neal Flomenberg were made solely to satisfy tax obligations linked to restricted stock units. Other key officers have not sold shares since the company's inception and have paid their tax obligations at grant. The company also announced projected revenue of $1 billion for its lead oncology candidate in the launch year and plans to release additional forecasts for non-oncology areas soon.
Read more →TVGNGeneral
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days
Tevogen Bio, a clinical-stage immunotherapy biotech, has expressed gratitude for unprecedented public support of its business model, centered on patient accessibility and innovative therapeutics. The company has launched its proprietary ExacTcell technology and achieved significant intellectual property milestones, including patents and positive clinical trial outcomes. Tevogen's commitment to its mission is evidenced by its leadership's retention of equity, which reflects confidence in the company’s potential for future success. The CEO plans to share further updates on the company's oncology pipeline and overall progress in the coming days.
Read more →TVGNGeneral
▲ +32.7%on this news· ran to +65% by day 1shared move
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion
Tevogen Bio has been recognized by Warren Township, NJ, for its pioneering business model aimed at alleviating health inequalities through innovative cell therapies. The company's founding CEO, Dr. Ryan Saadi, has also received a nomination for the 2023 Nobel Peace Prize, acknowledging their efforts to democratize access to life-saving therapies. Tevogen's market value is estimated to exceed $10 billion, spurred by a strong intellectual property portfolio and a promising product pipeline. Support from significant investors reinforces confidence in Tevogen's mission and future growth.
Read more →TVGNGeneral
▼ -24.1%on this newsshared move
Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality
Tevogen Bio has expressed gratitude to Warren Township for honoring CEO Dr. Ryan Saadi with a proclamation, highlighting his nomination for the Nobel Peace Prize and the company's mission to address health inequality. Dr. Saadi emphasized the importance of creating impactful changes beyond mere business metrics. Tevogen, a clinical-stage biotech focused on T cell therapeutics, reports positive safety outcomes from its trials and aims to make significant advancements in medical accessibility. The company possesses valuable intellectual property and seeks to innovate in the healthcare landscape.
Read more →TVGNPhases
▲ +25.7%on this news· ran to +58% by day 3shared move
Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions
Tevogen Bio is advancing the development of a new T cell therapy, TVGN 920, targeting HPV in women with precancerous cervical lesions. This investigational therapy aims to eradicate HPV and prevent recurrent lesions that may lead to cervical cancer. Manufactured with the company's proprietary ExacTcell™ technology, the therapy is currently undergoing safety and feasibility studies. Positive safety data from earlier trials bolster confidence in its potential to impact women's health significantly.
Read more →TVGNPhases
▲ +25.7%on this news· ran to +58% by day 3shared move
Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use
Tevogen Bio has published promising Phase I trial data for its investigational T-cell therapy, TVGN 489, aimed at treating SARS-CoV-2. The therapy was well-tolerated, showing significant viral elimination and symptom resolution in high-risk patients, including those immunocompromised. Notably, the treatment group exhibited no disease progression or Long COVID, highlighting the potential of TVGN 489. Tevogen's leadership sees this as a significant breakthrough in the field of off-the-shelf T-cell therapies.
Read more →TVGNGeneral
▲ +187.1%on this news· ran to +264% by day 3shared move
Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections
Tevogen Bio reaffirmed its commitment to enhancing shareholder transparency, particularly regarding its multi-billion-dollar asset valuation and recent revenue potential announcements exceeding $1 billion. CEO Ryan Saadi highlighted the positive trajectory of their pipeline, particularly for the COVID-19 therapy TVGN 489, which has shown promising proof-of-concept results. The company also emphasized its advancements in AI through Tevogen.AI, which has joined the Microsoft for Startups program. Tevogen's recognition as a high-value biotech unicorn reflects its impact and prospects in the industry.
Read more →TVGNGeneral
▲ +18.5%on this news· ran to +240% by day 1shared move
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
Tevogen Bio, a clinical-stage biotech firm, plans to announce its pipeline portfolio's over $1 billion revenue potential starting October 14, 2024. This potential is attributed to its unique, cost-effective drug development approach and a commitment to addressing significant health challenges. CEO Ryan Saadi expresses confidence in the company's business fundamentals, despite the inherent risks associated with capital requirements and regulatory processes. The announcement comes in light of Tevogen's recent business combination with Semper Paratus Acquisition Corporation, which may impact future operations.
Read more →TVGNGeneral
▲ +18.5%on this news· ran to +240% by day 1shared move
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
Tevogen Bio has announced an expansion of its therapeutic pipeline, focusing on oncology and Long COVID treatments. The company aims to address the high unmet needs of cancer patients using its ExacTcell™ technology platform. Additionally, the announcement highlights a strategic shift towards non-oncology products and a commitment to maximizing return on investment. However, the company faces potential challenges, including the need for additional capital and regulatory risks stemming from its recent business combination.
Read more →TVGNPhases
Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation
Tevogen Bio has announced promising topline results from its clinical trial of TVGN 489, a T cell therapeutic for acute high-risk SARS-CoV-2 patients. The trial showed no significant adverse effects and confirmed safety across all doses. Patients treated with TVGN 489 also demonstrated a rapid return to baseline health and no instances of reinfection or Long COVID at the six-month follow-up. The company's CEO emphasized the need for new treatments aimed at immunocompromised populations and expressed optimism for the potential impact of their technology on public health.
Read more →TVGNGeneral
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
Tevogen Bio has recently met with U.S. Congressional leaders to advocate for Long COVID patients, presenting its ExacTcell technology as a potential solution. The company highlighted significant progress with its lead product, TVGN 489, which is currently in clinical development for SARS-CoV-2 infections. Tevogen's leadership emphasized the importance of their intellectual property assets and innovative business model in driving future growth and addressing unmet medical needs. Additionally, they are focused on ensuring patient access to effective therapies through advanced science.
Read more →TVGNGeneral
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
Tevogen Bio has announced a $6 million Series C Preferred Stock investment from The Patel Family, LLP, aimed at advancing its innovative T cell therapeutics. The funding will occur in two closings, with the first set for August 30, 2024. Tevogen's leadership believes that their focus on advanced science can address unmet medical needs in oncology and infectious diseases. Positive clinical trial data supports their growth, though they face challenges such as potential regulatory hurdles and additional funding requirements for future projects.
Read more →TVGNGeneral
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
Tevogen Bio Holdings Inc. reported its financial results for Q2 2024, demonstrating that it has sufficient cash and resources to continue operations for at least another year. The company eliminated concerns about its going concern status after securing preferred stock financing. Furthermore, Tevogen repurchased its Series B preferred shares, enhancing its financial positioning. Despite these positives, the company faces significant non-cash expenses and continues to rely on future financing.
Read more →TVGNGeneral
▲ +6.6%on this newsshared move
Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
Tevogen Bio announces that Professor Sten Vermund has been appointed as Dean of the USF Health College of Public Health, beginning January 1, 2025. Dr. Vermund will continue his leadership role at the Global Virus Network, contributing to public health initiatives and combating pandemic threats. Tevogen Bio emphasized its pride in Dr. Vermund's achievements and its commitment to developing innovative T cell therapies for various diseases, backed by positive safety data from clinical trials.
Read more →TVGNGeneral
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
Tevogen Bio Holdings Inc. has reaffirmed that its recently effective Registration Statement on Form S-1 does not pertain to any undisclosed new issuance of dilutive securities. CEO Ryan Saadi emphasized the company's commitment to its growth strategy and mission to deliver affordable and accessible therapies. The registration statement includes provisions related to previously disclosed warrants and shares, focusing on enhancing shareholder value while navigating market volatility. Tevogen is advancing its innovative, off-the-shelf T cell therapeutics for oncology, neurology, and virology.
Read more →TVGNGeneral
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
Tevogen Bio has released a letter to stockholders outlining recent achievements and future plans, including the progress of its lead candidate TVGN 489 for treating COVID-19 in cancer patients. The company is also advancing treatments for various cancers and exploring a potential share buyback to enhance shareholder value. Additionally, Tevogen continues to develop its predictive modeling platform, Tevogen.AI, and remains committed to transparency with stockholders. However, challenges related to the execution of growth strategies and the need for capital to support its plans are acknowledged.
Read more →TVGNGeneral
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
Tevogen Bio is focusing on its ExacTcell platform, which helps produce off-the-shelf, genetically unmodified T cells for various diseases including cancers and neurological disorders. With advancements in T cell therapy, the leadership highlighted the importance of overcoming barriers to patient accessibility and affordability. The recent phase I clinical trial showed promising safety data, indicating no dose-limiting toxicities. Tevogen aims to make cytotoxic T cell therapy a routine outpatient treatment, expanding its potential patient base significantly.
Read more →TVGNGeneral
▲ +7.4%on this news
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
Tevogen Bio Holdings Inc. has filed a Registration Statement on Form S-1 to register shares of common stock following previously disclosed arrangements, including warrants and earnout shares from prior agreements. The statement clarifies that it does not relate to any undisclosed new issuances of dilutive securities. Currently, the registration statement awaits effectiveness by the SEC. Tevogen Bio is focused on developing genetically unmodified T cell therapies for oncology, neurology, and virology, supported by positive clinical trial data and a solid patent portfolio.
Read more →TVGNPhases
▼ -10.4%on this newsshared move
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
Tevogen Bio Holdings Inc. announced the publication of positive Phase I clinical trial results for its investigational therapy TVGN 489, designed for SARS-CoV-2. The trial involved twelve high-risk patients, revealing that 92% achieved significant viral elimination within four days, with no disease progression noted. The treatment demonstrated good tolerability and persistence of the T-cells post-infusion. These findings suggest potential for further development in treating COVID-19, especially among vulnerable populations.
Read more →TVGNConferences/Events
▼ -8.3%on this news
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
Tevogen Bio Holdings, a clinical-stage biotech firm, presented its innovative approach to T cell therapies at the Longwood Spring MIT Conference. Chief Information Officer Mittul Mehta highlighted the company's commitment to addressing industry challenges, focusing on the development of off-the-shelf, genetically unmodified T cell therapeutics. Tevogen's unique ExacTcell platform aims to increase accessibility and reduce manufacturing costs for treating a range of medical conditions. While the company has achieved positive clinical trial results, potential challenges related to funding and regulatory processes remain.
Read more →TVGNGeneral
Tevogen Bio Set to Join Russell 3000 Index
Tevogen Bio Holdings Inc. is poised to join the Russell 3000 Index effective July 1, 2024, enhancing its visibility and credibility in the investment market. The Russell Indexes are extensively utilized by investment managers and institutional investors, representing a significant benchmarking framework. Tevogen is focused on developing innovative off-the-shelf, genetically unmodified T cell therapies targeting oncology, neurology, and virology, and has reported positive results in its clinical trials. The leadership emphasizes the importance of accessibility and sustainability in advancing medical innovation.
Read more →TVGNGeneral
▲ +6.5%on this newsshared move
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
Tevogen Bio has finalized a financing agreement for up to $50 million, which includes a $36 million line of credit and a $14 million private placement. This funding aims to enhance its research and development, particularly of its ExacTcell™ technology and strengthen its intellectual property portfolio. Following the elimination of $94.9 million in liabilities, Tevogen is positioned to make significant investments in its product pipeline. The company is optimistic about expanding patient access to its innovative therapies, although challenges remain regarding additional funding and regulatory hurdles.
Read more →TVGNGeneral
▲ +14.9%on this newsshared move
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
Tevogen Bio, a clinical-stage immunotherapy company, hosted its first social engagement event on May 31, 2024, to connect with patients, elected officials, and first responders. The event highlighted Tevogen's innovative approach to precision T cell therapies and aimed to address unmet healthcare needs. CEO Dr. Ryan Saadi expressed gratitude towards attendees for their interest and shared insights on improving patient outcomes while reducing healthcare costs. The company is progressing with promising clinical data and owns its key intellectual property assets.
Read more →TVGNPhases
▲ +14.9%on this newsshared move
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
Tevogen Bio announced that its investigational immunotherapy, TVGN 489, continues to demonstrate efficacy against the FLiRT strains of SARS-CoV-2, which are currently prevalent variants. In previous trials, high-risk patients treated with TVGN 489 showed significant clinical improvement without any major adverse effects. The company is committed to further development and potential treatment options for patients at high risk for severe COVID-19 outcomes and those suffering from Long COVID. Tevogen also emphasizes the sustainability of its product's efficacy due to the broad targeting of SARS-CoV-2 peptides.
Read more →TVGNGeneral
Tevogen Bio Reports First Quarter 2024 Financial Results
Tevogen Bio Holdings Inc. announced its financial results for Q1 2024, revealing the elimination of $94.9 million in liabilities through converting promissory notes into equity. The report highlighted an operating cash expenditure of $2.1 million, with substantial non-cash expenses attributed to stock-based compensation. CEO Ryan Saadi emphasized the company's commitment to addressing Long COVID through innovation in T cell therapies. Tevogen has successfully completed initial clinical trials and aims to leverage its strong intellectual property portfolio for future growth.
Read more →TVGNGeneral
▼ -8.2%on this news
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
Tevogen Bio has appointed William Keane, a former police chief with 35 years of leadership experience, as Vice President of Strategic Initiatives. His role will focus on ensuring compliance with regulatory guidelines and aiding in the procurement of lab space. The company continues to develop innovative T cell therapies for various diseases and boasts entirely owned intellectual property assets, including several patents. This strategic leadership move aims to bolster Tevogen's mission to enhance patient accessibility and drive medical innovation.
Read more →TVGNGeneral
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
Tevogen Bio has announced a financing deal of up to $50 million to enhance its research and development initiatives, particularly for its TVGN 489 product. The funds will support the expansion of clinical trials focusing on virally induced cancers and multiple sclerosis. This financing includes a $36 million line of credit and a $14 million private placement, aimed at minimizing shareholder dilution. Positive proof-of-concept results from previous trials further enhance the potential for Tevogen's innovative therapies.
Read more →TVGNGeneral
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
Tevogen Bio Holdings Inc. has released its financial results for the fiscal year 2023 and highlighted key operational objectives, including the acquisition of a cell therapy manufacturing facility. The company aims to further develop its ExacTcell technology platform, having demonstrated positive proof-of-concept trial results for its treatment, TVGN 489, intended for high-risk patients. Tevogen is focusing on addressing the therapeutic potential of its candidates for Long COVID while evaluating various funding options to support its growth. Despite the positive outlook, there are notable risks associated with the acquisition process and the need for additional capital.
Read more →TVGNGeneral
▲ +17.6%on this newsshared move
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments Conversion of promissory notes into common stock removed $94.9 million in pro forma balan
Tevogen Bio Holdings Inc. has announced a significant financial improvement as the conversion of promissory notes into common stock has eliminated $94.9 million in liabilities. This change reflects positively on the company’s balance sheet, which totals 165 million outstanding shares. Additionally, Tevogen has launched the Tevogen.ai initiative, aiming to leverage artificial intelligence to enhance various aspects of drug development. New leadership appointments in technology and investor relations further strengthen the company's strategic direction.
Read more →TVGNPhases
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
Tevogen Bio Holdings announces an optimistic outlook following the successful proof-of-concept for TVGN 489, which demonstrated the ability to target and eliminate a virus in a high-risk population. The company aims to leverage its ExacTcell technology to develop products targeting cancer-associated viruses like HPV and EBV. Tevogen's Chief Scientific Officer explained the role of cytotoxic T lymphocytes in treating virally driven cancers, indicating potential benefits in preventing or minimizing surgical interventions. However, the company acknowledges various uncertainties and risks related to future growth and regulatory challenges.
Read more →TVGNGeneral
▼ -11.2%on this news
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
Tevogen Bio Holdings Inc (Nasdaq: TVGN) has appointed Tapan V Shah as the new Head of Investor Relations and Corporate Development. Shah brings over 25 years of experience from notable firms like Citigroup and Goldman Sachs, positioning him to lead financial communications and M&A activities. His leadership is expected to support Tevogen Bio's growth strategies as the company aims to expand its presence in the healthcare sector, notably in precision T cell therapies. The company also reports positive safety data from its clinical trials, underscoring its commitment to innovative therapeutics.
Read more →TVGNGeneral
▲ +8.1%on this news· ran to -25% by day 3shared move
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
Tevogen Bio has announced an investment agreement that will result in the issuance of Series A-1 Preferred Stock, valued at an aggregate of $6.0 million. This investment comes with a raised conversion price of $10.00 per share, reflecting the investor's confidence in Tevogen's innovative T cell therapy platform. The company is focused on developing advanced immunotherapies to treat conditions such as Long COVID, cancer, and neurological disorders, with a robust business model that emphasizes sustainability and patient accessibility. Tevogen reports positive advancements in its clinical trials and holds significant intellectual property assets.
Read more →TVGNGeneral
▼ -10.7%on this news· ran to -24% by day 3shared move
Tevogen Bio Announces Series A-1 Preferred Stock Investment
Tevogen Bio has announced a $6 million investment through a securities purchase agreement for newly designated Series A-1 Preferred Stock. This investment reflects the confidence of an existing investor in Tevogen's ExacTcell platform, which aims to develop off-the-shelf T cell therapies for various conditions including Long COVID and cancer. The newly issued shares will have a higher conversion price compared to the previous Series A Preferred Stock, indicating a positive outlook for the company’s commercial prospects. Tevogen continues to advance its mission of patient accessibility through innovative treatments and business models.
Read more →TVGNGeneral
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN
Tevogen Bio Holdings Inc. has successfully completed its business combination with Semper Paratus Acquisition Corporation and will begin trading on Nasdaq under the ticker TVGN starting February 15, 2024. The new entity aims to enhance access to capital and accelerate the development of its genetically unmodified T cell therapy products, targeting large patient populations across various medical conditions. The company's leadership emphasizes a focus on affordability and precision in developing innovative therapies to address unmet healthcare needs. The listing is seen as a transformative step for the company's growth and market presence.
Read more →TVGNGeneral
Semper Paratus Acquisition Corporation's Shareholders Approve Business Combination with Tevogen Bio New York, NY
Semper Paratus Acquisition Corporation has received shareholder approval for its business combination with Tevogen Bio. This merger will allow Semper Paratus to bring Tevogen's innovative immunotherapy solutions to market, with trading expected under the TVGN ticker post-completion. The completed transaction hinges on satisfying additional closing conditions outlined in their proxy statement. The merger aligns with Tevogen's commitment to addressing unmet medical needs through advanced T cell therapies.
Read more →TVGNGeneral
Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq New York, NY
Semper Paratus Acquisition Corporation has announced plans to list Tevogen Bio Holdings Inc. on Nasdaq following a merger agreement. A supplement to the proxy statement was filed, updating the listing plan from NYSE American to Nasdaq. Tevogen Bio focuses on developing precision T cell therapies for various medical conditions and has reported positive trial results. The merger is set for a shareholder vote on January 29, 2024, and could potentially enhance Tevogen Bio's market position through increased accessibility and innovative development models.
Read more →TVGNGeneral
Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination The pro forma equity value of the portion of the combined company attributable to Tevo
Tevogen Bio Inc. and Semper Paratus Acquisition Corporation have announced the effectiveness of their registration statement for a business combination, with an anticipated equity value of $1.2 billion attributable to Tevogen stockholders. The transaction aims to close after shareholder approvals. Upon completion, Tevogen Bio will be renamed Tevogen Bio Holdings Inc. The CEOs of both companies express optimism about the merger's potential to create accessible therapeutic solutions, although the announcement also outlines several risks related to its completion and market reactions.
Read more →TVGNGeneral
Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement New York
Semper Paratus Acquisition Corporation has announced that it has regained compliance with the Nasdaq Listing Rule requiring a Market Value of Listed Securities (MVLS) of $50 million. This compliance was confirmed in a letter from the Listing Qualifications Department of Nasdaq, noting that the company maintained an MVLS above this threshold for ten consecutive business days from September 14 to September 27, 2023. The announcement reflects the company's improved standing and its ability to meet regulatory requirements.
Read more →TVGNGeneral
Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc New York, NY
Semper Paratus Acquisition Corporation has filed a registration statement with the SEC regarding its planned merger with Tevogen Bio Inc., a biotech firm specializing in immunotherapy. The proposed transaction is set to create Tevogen Bio Holdings Inc., which focuses on developing personalized T cell therapies. While the merger has board approval, it is subject to SEC review and requires shareholder and regulatory approvals. The transaction is anticipated to finalize by the end of 2023, subject to several customary closing conditions.
Read more →TVGNGeneral
Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation Tevogen Bio Inc. ("Tevogen Bio") is an advanced-stage specialty immunotherapy biotech pioneer developing
Tevogen Bio Inc. is set to become publicly listed on the NYSE through a merger with Semper Paratus Acquisition Corporation. This collaboration aims to capitalize on Tevogen Bio's advanced immunotherapy platform, ExacTcell, which focuses on developing unmodified T cell therapies for various diseases. The merger, expected to conclude in Q4 2023, will provide Tevogen with approximately $1.2 billion in pro forma equity value, enabling the acceleration of its clinical pipeline, particularly its lead therapy, TVGN 489, targeted for immunocompromised patients. Tevogen Bio aims to make significant strides in patient access and affordability in immunotherapy treatments.
Read more →TVGNGeneral
Semper Paratus Acquisition Corporation Announces the Separate Trading of its Class A Ordinary Shares and Warrants New York, NY
Semper Paratus Acquisition Corporation Announces
the Separate Trading of its
Class A Ordinary Shares and Warrants
New York, NY - December 30, 2021 - Semper Paratus
Acquisition Corporation (Nasdaq: LGSTU) (the "Company") announced today that, commencing January 3, 2022, holder
Read more →TVGNGeneral
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of Semper Paratus Acquisition Corporation Opinion on the Financial Statement We have audited the accompanying balance she
tm2132608d1_ex99-1.htm
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
To the Shareholders and Board of Directors of
Semper Paratus Acquisition Corporation
Opinion on the Financial Statement
We have audited the accompanying balance sheet
of Semper Paratus Acquisition Cor
Read more →TVGNGeneral
Semper Paratus Acquisition Corporation Announces Pricing of $300 Million Initial Public Offering
Semper Paratus Acquisition Corporation Announces
Pricing of $300 Million Initial Public Offering
November 3, 2021 [5:00] PM Eastern Daylight
NEW YORK-(CISION PR NEWSWIRE)-Semper
Paratus Acquisition Corporation (the "Company") announced today that it priced its initial public
Read more →